The first book to collect and synthesize cutting-edge research findings on the treatment of gynecological malignancies into one easy-to-use reference, Clinical Trials in Ovarian Cancer provides physicians with an invaluable resource. Gynecologic oncologist Christine S. Walsh systematically outlines each of the seminal Phase III trials that have shaped the treatment of ovarian cancers, detailing the rationale for the trial, the patient population studied, treatment delivery methods, efficacy, toxicity, and trial conclusions
The Gynecologic Cancer Intergroup is comprised representatives from international gynecological canc...
The development of modern technologies has revolutionised science and has had a huge impact on biome...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
AIMS: To review the most important clinical trials which have impacted the management of gynaecologi...
Ovarian cancer management is a rapidly changing field with new treatment agents available as a resul...
Introduction: ovarian cancer is one of the most common and lethal tumor in women. This happens as a ...
The annual incidence rate of cancer is estimated to be more than 11,000 patients in the U.K. in the ...
Ongoing and effective collaboration with industry, government, and patients aims to ensure that the ...
Ovarian cancer is a leading cause of gynecological cancer-related deaths in women worldwide. Due to ...
The cancer that originates in ovary is one of the most deadly gynecological malignancies. Despite ad...
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highes...
Fig 1 depicts an overview on the search strategy to identify relevant ovarian cancer clinical trials...
Despite the many advances in the diagnosis and treatment of ovarian cancer over the past four decade...
Ovarian cancer is the leading cause of gynecologic cancer death among women in the United States, cl...
Objective As a result of relevant achievements in the field of translational research, several activ...
The Gynecologic Cancer Intergroup is comprised representatives from international gynecological canc...
The development of modern technologies has revolutionised science and has had a huge impact on biome...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...
AIMS: To review the most important clinical trials which have impacted the management of gynaecologi...
Ovarian cancer management is a rapidly changing field with new treatment agents available as a resul...
Introduction: ovarian cancer is one of the most common and lethal tumor in women. This happens as a ...
The annual incidence rate of cancer is estimated to be more than 11,000 patients in the U.K. in the ...
Ongoing and effective collaboration with industry, government, and patients aims to ensure that the ...
Ovarian cancer is a leading cause of gynecological cancer-related deaths in women worldwide. Due to ...
The cancer that originates in ovary is one of the most deadly gynecological malignancies. Despite ad...
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highes...
Fig 1 depicts an overview on the search strategy to identify relevant ovarian cancer clinical trials...
Despite the many advances in the diagnosis and treatment of ovarian cancer over the past four decade...
Ovarian cancer is the leading cause of gynecologic cancer death among women in the United States, cl...
Objective As a result of relevant achievements in the field of translational research, several activ...
The Gynecologic Cancer Intergroup is comprised representatives from international gynecological canc...
The development of modern technologies has revolutionised science and has had a huge impact on biome...
Introduction: Ovarian cancer is the most lethal gynecologic malignancy. Over 5200 new cases of this ...